Liva Nova

‘Mea culpa’: What Goldman Sachs analysts got wrong about Medtronic in 2022
Medtech Dive
Thu, 01/5/23 - 10:02 am
devices
Medtech
Goldman Sachs
Liva Nova
Medtronic